K2 Principal Fund’s ProKidney PROK Stock Holding History

K2 Principal Fund’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-136,937	Closed	-$1.37M	–	331
2022 Q2	$1.37M	Buy	+136,937	New	+$1.35M	0.15%	137
2022 Q1	–	Sell	-100,000	Closed	-$990K	–	343
2021 Q4	$990K	Sell	100,000 -39,524	-28%	-$391K	0.07%	181
2021 Q3	$1.37M	Sell	139,524 -10,476	-7%	-$103K	0.11%	162
2021 Q2	$1.52M	Buy	+150,000	New	+$1.52M	0.13%	194

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

K2 Principal Fund's PROK Position: Q3 2022 in Review

K2 Principal Fund sold out of ProKidney (PROK) in Q3 2022, closing a stake of 136,937 shares — an estimated $1.37M sold.

K2 Principal Fund first reported a position in PROK in Q2 2021 and held it in 4 quarters. The position peaked at $1.52M in Q2 2021. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

K2 Principal Fund reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
K2 Principal Fund sold 136,937 ProKidney shares in Q3 2022, an estimated $1.37M.
K2 Principal Fund first reported a position in ProKidney in Q2 2021 and held it in 4 quarters.
K2 Principal Fund's ProKidney position peaked at $1.52M in Q2 2021.
18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on K2 Principal Fund's 13F filing for Q3 2022, filed 14 Nov 2022.